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Type II diabetes is a highly prevalent disease in the world that is associated with many 
complications such as heart disease, stroke, hypertension, and blindness. It is a disease caused by 
an insufficient production of insulin or insensitivity to insulin, leading to higher blood glucose 
levels. One of the ways in which secretion is regulated is through the action of an incretin 
hormone, glucagon-like peptide-1 (GLP-1), which binds to the glucagon-like peptide-1 receptor 
(GLP-1R) in the pancreatic beta cells, causing the release of insulin into the bloodstream. 
 
Common methods to combat type II diabetes include direct insulin injection, GLP-1 mimetics, 
and dipeptidyl peptidase IV (DPP IV) inhibitors. Current treatments are mostly peptide based 
and are highly susceptible to degradation, thus lowering the efficacy of the drug. Likewise, direct 
administration of GLP-1 is inefficient since its half-life is around two minutes in vivo.  
 
In order to extend the effectiveness of the drug, small non-peptidic agonists of GLP-1R have 
been investigated. However, the development of such agonists requires characterization 
information about GLP-1R such as the important residues that help small molecules bind to the 
receptor as well as the residues that are important for the initiation of the production of insulin. A 
small molecule inverse agonist called T-0632 has affinity to GLP-1R and inhibits GLP-1 induced 
cAMP production in a concentration-dependent manner. Thus, our goal is to synthesize 
photolabile analogs of T-0632 that will allow for characterization of the important residues in the 
GLP-1R binding pocket.  
 
Synthesis of a photolabile analog of T-0632 begins with iodination of the molecules leading up 
to T-0632. Iodine is then displaced by an azide, and when this azide group interacts with UV 
light, it is converted into a highly reactive nitrene group that covalently binds to the nearest 
residue in the binding pocket. This thesis focuses on the first and third steps of the overall 
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1.1 Background on Type II Diabetes 
Diabetes mellitus is a prevalent disease in the world, affecting as many as 25.8 million 
Americans of all ages as of 20111 and 382 million people in the world.2 It is estimated that the 
number of people in the world living with diabetes will increase to 592 million by 2035.2 Of the 
three main types of diabetes, type II diabetes is the most common and makes up about 90 to 95 
percent of diabetic patients.3 Diabetes is associated with many complications such as heart 
disease, stroke, hypertension, blindness, kidney disease, and nervous system disease.1  
Type II diabetes mellitus is a disease that is characterized by insulin resistance, even in 
the case where the pancreas is producing a normal amount of insulin. The inefficiency of the 
body in its use of insulin gradually puts stress on the pancreas and causes the organ to stop 
producing the needed amount after several years.1, 3  
As a result of this, patients with type II diabetes have higher blood glucose levels as 
compared to that of healthy individuals. Type II diabetes is often correlated with factors such as 
family history of diabetes, older age, obesity, and race/ethnicity.1 It is also of note that higher 
prevalence of obesity and diabetes among adults living in high-poverty areas have been 
observed, even after standardizing for individual education, income, and occupation.4  
Despite its prevalence and associations with many other diseases, there are limited 
treatment options for type II diabetes, which fall under two categories: insulin injection or oral 
medication.1 Insulin therapy can induce weight gain and increase the patient’s risk of 
hypoglycemic episodes. Some oral medication types such as sulfonylureas or metiglinides are 
often associated with unwanted weight gain and increased hypoglycemic occurrences. 
Additionally, these therapies do not change or hinder the progression of type II diabetes; they 
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only act as quick insulin boosters.5 Needless to say, there is still a lot of research to be done on 
the current treatment options for type II diabetes. 
1.2 Glucagon-like Peptide 1 and Glucagon-like Peptide 1 Receptor  
Investigation of a better treatment method for type II diabetes begins with understanding 
the mechanism of insulin production. There are many pathways in the body that control for 
glucose homeostasis, and one of the pathways involves the actions by incretin hormones, GIP 
and GLP-1R. In fact, the insulinotropic effect by the incretin hormones account for 60% of the 
secreted insulin after a meal.6 GLP-1 is further divided into two active forms, 80% of which is 
GLP-1 (7-36) amide and the remaining 20% being GLP-1 (7-37).6 After a meal, the K-cells and 
the L-cells of the intestine secrete GIP and GLP-1 respectively, which then stimulate the GLP-1 
receptor (GLP-1R) of the pancreatic β cells to secrete insulin (figure 1).6-7 
 
 
Figure 1. Production and the action of incretins in glucose homeostasis. Image taken from Ross and Ekoé.7 
 
In type II diabetic patients there is a decrease in stimulation of insulin secretion by 
exogenous GIP and GLP-1 by 54% and 29% respectively as compared to healthy subjects. 
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However, the glucose lowering effect by GLP-1 is relatively preserved unlike that of GIP, in 
which the glucose lowering effect is absent.6  
The relatively high efficacy of GLP-1 to lower glucose even in type II diabetic patients 
makes it an attractive therapeutic strategy. In addition, the ability of GLP-1 to amplify insulin 
release in a glucose-dependent manner makes it a promising target for clinical research.8 It 
should be noted, however, that hormone treatment with GLP-1 itself is not ideal since its half-life 
in vivo is around 2 minutes. GLP-1 and GIP are both rapidly degraded at the N-terminus by the 
enzyme dipeptidyl peptidase IV (DPP IV). After incretins undergo cleavage, the remaining 
pieces of the hormone no longer have insulinotropic activity.9 The only effective way to use 
GLP-1 hormone treatment would be a direct and continuous administration of GLP-1 into the 
veins whenever a patient is having a meal, which is considered to be a highly impractical 
solution to most patients. 
1.3   Peptide GLP-1R agonists 
The impracticality of direct hormone therapy opens up two new research areas: the 
development of GLP-1 mimetics and enhancers. Figure 2 shows the classification of GLP-1 
related therapies for type II diabetes currently in clinical use or in development. Generally, GLP-
1R agonists are divided into two categories: short-acting or long-acting. These compounds differ 
in their pharmacokinetics, implying that there are fundamental differences in the mechanism of 
action, efficacy, and viability.10 Short-acting compounds are characterized by the sharp rise in 
plasma peptide levels when administered11 whereas long-acting compounds are identified by 







Figure 2. Classification of GLP-1 therapies. Figure adapted from Cho et al.13 
The above figure shows that there are many ways to modify the GLP-1 pathway by 
improving in vivo half-life of GLP-1. One way to extend the half-life is to reduce the cleavage 
done by DPP IV. Exendin-4 based agonists, exenatide and lixisenatide, have molecular 
modifications in which the second and the third amino acids of the peptide at the N-terminal 
positions are exchanged, which results in resistance to cleavage by DPP IV.14 However, exendin-
4 based agonists are still subjected to renal degradation9; consequently a limit is put on the half-
life. 
To avoid degradation by both DPP IV and renal elimination, a plasma albumin can be 
used to bind to the peptide14 using two different binding types. Liraglutide is an example of a 
long-acting, noncovalent attachment to albumin, in which a 16-carbon fatty acid chain is 
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conjugated to the peptide. Albiglutide and dulaglutide, also long-acting agonists, are covalently 
associated with albumin or immunoglobulin G, respectively, to avoid renal elimination.10  
Another type of GLP-1R agonist is exenatide-LAR (long-acting release), which has a 
prolonged in vivo half-life and extended release of hormone due to its coupling to polymer 
microspheres. Coupling of GLP-1 with chemicals like zinc has also shown a delay in absorption 
by subcutaneous tissue.10 These various peptide GLP-1R agonists are summarized in figure 3 
below. 
 
Figure 3. Types of peptide GLP-1R agonists and their mechanism of action. Various strategies were used 
in order to prolong in vivo half-lifes. a) exendin-4 based agonists, b) taspoglutide, c) albiglutide and 
dulaglutide, d) liraglutide, and e) exenatide-LAR. Figure adapted from Meier.10 
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With any treatment there are side effects and drawbacks. These short-acting and long-
acting agonists are known to exhibit side effects such as induced nausea, vomiting, and local skin 
reactions around the injection site.10 Another crucial drawback is that these agonists are protein 
based, meaning they require a syringe to deliver into the body as opposed to oral administration.  
1.4   Small molecule GLP-1R agonists 
Small molecule GLP-1R agonists under the category of GLP-1 mimetics in figure 2 are 
interesting but difficult compounds to research. Developing a small molecule agonist, preferably 
in pill form, requires the knowledge of the active site of the receptor as well as the important 
functional groups for binding and activation. In terms of GLP-1R, a class B G-protein coupled 
receptor (GPCR), a three-dimensional structure of intact receptors is unavailable, leading to 
uncertainty in the basis of ligand binding and what it takes to activate the receptor.15  
Previous research has been done to mimic the secondary structures such as α-helices and 
β-turns of proteins, due to their likely role in the inhibition/facilitation of the protein-protein 
interaction. For example, a study done by Han et al. looked at an α-helix mimic of GLP-1 in 
hopes to develop a small molecule agonist of GLP-1R (figure 4).  
 
 
Figure 4. Tris-benzamides as an α-helix mimic of GLP-1.  












When three of the synthesized tris-benzamides were tested with human GLP-1R over-
expressed on COS-7 cells, stimulation of cAMP production was observed, confirming the 
agonistic nature of these small molecules.16 
Further investigation of such small molecule agonists of GLP-1R is valuable due to their 
practicality as a drug. Unlike hormonal treatment, these agonists can potentially be administered 
orally, increasing their feasibility as a treatment method. 
1.5   T-0632, a small molecule inverse agonist of GLP-1R 
A small molecule non-peptide ligand called T-0632 (T-06) was originally synthesized by 
a Japanese pharmaceutical company for the treatment of pancreatitis as a cholecystokinin-1 
(CCK1) antagonist (figure 5).17 T-06 binds to the CCK1 receptor (CCK1R, a class A GPCR) in a 
concentration dependent, competitive manner for this inhibitory effect.18 
 
Figure 5. T-0632 
Like any drug, there were side effects to T-06, the biggest and the most surprising of 
which was the inhibition of GLP-1 induced cAMP production in a concentration-dependent 
manner as Tibaduiza et al. reported in 2001.19  
 Comparative binding studies of T-06 with human and rat GLP-1R showed that T-06 has 
almost 100-fold selectivity to human GLP-1R over rat GLP-1R despite a 91% amino acid 











competition binding experiments were done, which determined that the amino terminus is 
important for such selectivity. When the amino terminus of the rat GLP-1R was partially 
substituted with the comparable amino acid sequence from human GLP-1R, a higher T-06 
affinity to rat GLP-1R was observed. Tryptophan 33 in human GLP-1R was found to be an 
important residue in additional studies done to identify a single residue that determines species 
selectivity to non-peptide binding. When tryptophan 33 was substituted in place for serine 33 in 
rat GLP-1R, there was a 100-fold increase in T-06 affinity. The reciprocal 100-fold loss of T-06 
affinity was observed for the converse mutation of human GLP-1R.19  
 The work done by Tibaduiza et al. provided important initial insights into what 
determines non-peptide affinity to a class B receptor, which they suggest it to be in the 
extracellular amino-terminal domain.19 Looking ahead, additional binding studies with T-06 may 
provide valuable information in the development of a small molecule agonist of GLP-1R. 
1.6 Photoaffinity labeling 
As mentioned earlier, knowing the important residues in the binding site of GLP-1R is 
crucial when developing a small molecule agonist. In order to map out the binding pocket, some 
type of a visualization technique is needed. The schematic diagram of photoaffinity labeling is 
shown in figure 6 below. A natural or chemically modified substrate binds to the enzyme in a 
reversible manner. When the enzyme-substrate complex is exposed to light, a covalent bond 
forms between the enzyme and the substrate. The photolabeled enzyme is then digested with 
enzymes to give the labeled fragment.20 
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Figure 6. Schematic diagram of photoaffinity labeling. Figure adapted from Fleming.20 
A study done by Dong et al. utilizes photoaffinity labeling using a known radioiodinated 
version of a small molecule pentapeptide NRTFD (Asn-Arg-Thr-Phe-Asp) in order to identify 
the active site in GLP-1R.15 Similarly, photoaffinity labeling studies using T-06 could yield 
valuable information to discern the important residues in the binding pocket of GLP-1R. 
The labeling method that is of interest in the Haines lab is the use of an azide. We take 
iodinated T-06, replace I with an azide, and expose the azide group to UV light. Once exposed to 
UV light, the azide group degrades into a highly reactive nitrene intermediate, which then inserts 
into the closest amino acid residue in the receptor to form a covalent bond to it. The labeled 
receptor is then digested with selective proteases into several fragments to be examined in 
determining the amino acid residue that has been bound by the photoaffinity label. 
1.7   Synthetic Goal of this Project 
The goal of this project is to synthesize many photolabile analogs of T-06 to map out the 
binding site of GLP-1R. As mentioned before, the photoaffinity labeling method used in the 
Haines lab is the use of an azide, prepared via an iodine substituent. Figure 7 shows all of the 
possible placements of iodine in T-06.  
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Figure 7. Possible places of iodination in T-06, indicated by nine asterisks. 
In vitro testing, done at the Mayo Clinic in Arizona, is currently done with CCK1R rather 
than with GLP-1R due to the higher binding affinity of T-06 to CCK1R than to GLP-1R. Though 
at first glance it may seem illogical to test azido T-06 on CCK1R in order to study the binding 
interaction between T-06 and GLP-1R, there are several reasons to justify this cross referencing 
between two different classes of GPCRs. 
CCK1R and GLP-1R are both GPCRs and have seven transmembrane domains, with N-
terminal domains in the extracellular space. Additionally, compensatory mechanisms involving 
these two receptors have been observed in genetically altered mice with deletions of the 
glucagon receptor (Gcgr) and GLP-1. These mice actually exhibited improved oral glucose 
tolerance as well as an increase in β cell activity in the pancreas. This was a surprising result, 
since two of the major insulinotropic β cell receptors have been deleted. One of the reasons for 
this improved function was due to a compensatory expression and activity of the CCK1R, which 
portrays remarkable adaptability of the mechanism in which these receptors manage glucose 
homeostasis.21 Such similarity and plasticity between GLP-1R and CCK1R allows for initial 
binding studies to be done on CCK1R. Additionally, since T-06 binds to GLP-1R in the 


















be done with lower concentrations of T-06. Thus CCK1R binding studies are not only 
economically advantageous but also beneficial in terms of obtaining greater certainty of 
specificity of the binding site. Eventually, when T-06 is made in greater yield, binding studies 
will be done on GLP-1R as well.  
T-06 analogs with varying iodine placements will give information about different parts 
of the binding pocket of the receptor. These pieces of information can then be assembled 
together to gain an understanding of the three dimensional picture of the receptor. Figure 8 




Figure 8. Overall synthetic scheme of T-06 (6). 
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My role in this project is in two parts. First, improve the first few steps of the overall 
scheme in the synthesis of diphenylamine (1). In the past this was done via nucleophilic aromatic 
substitution, which resulted in many side reactions and low yield. My goal was to develop a new 
method that will increase yield and convenience. 
My second goal was to find another method to accomplish the synthesis of Amine-HCl 
(3). In the past this reductive amination was done using oxime as an intermediate and catalytic 
hydrogenation (5% Pd on C, 50 psig of H2) as a reducing method. While this method was 
successful in reducing oxime to amine, it additionally cleaved the iodine (figure 9). 
 
Figure 9. Cleavage of iodine due to catalytic hydrogenation of oxime. 
The iodine plays a crucial role in synthesizing azido T-06 and must be preserved. My 
goal was to find other reductive amination methods that keep the iodine intact. Such a method 
would then allow for early iodination of the precursors leading to T-06 in locations that are 
unavailable for iodination later on in the synthesis. This greatly improves the flexibility of the 
synthetic scheme and also opens up a possibility of having multiple iodinated places in one 
analog. 
Investigation of the use of sulfimines, t-butyl protected imines, and hydroxyoxindoles as 




























Results and Discussion 
2.1   2-Fluoro-N-(3-methoxyphenyl)aniline (1) synthesis 
Previous efforts to synthesize 2-fluoro-N-(3-methoxyphenyl)aniline (1) (referred to as 
diphenylamine for short) were done via nucleophilic aromatic substitution. In this method, a 
basic reagent was used to deprotonate the amine group of m-anisidine to create a nucleophile, 
which then reacted with the electrophilic carbon of difluorobenzene to displace one of the 
fluorides. Unfortunately, due to the highly reactive nucleophile and excess difluorobenzene, 
some side reactions occurred with additional nucleophilic aromatic substitution reactions to yield 
triphenylamine and a black tar-like substance. The best yield obtained from this reaction was 
16% after a 72-hour reaction time.22 
Investigation of another method to synthesize diphenylamine (1) involved a copper 
catalyzed coupling reaction of phenylboronic acids and 2-fluoroaniline using a modified Chan-
Lam coupling mechanism (figure 10).23  
 
Figure 10. Mechanism of Chan-Lam coupling reaction. 
The reaction first starts with the deprotonation of the amine in 2-fluoroaniline, which is 































to the copper (II) acetate. Myristic acid helps to increase the solubility of the copper catalyst by 
coordinating to the copper center.23 Transmetallation of the copper (II) complex and the boron 
complex follows. During the transmetalation process, the copper metal needs to oxidize from 
Cu2+ to Cu3+, which is accomplished by utilizing O2 more efficiently through a vigorous stirring 
experimental condition. This tri-phenyl Cu3+ complex then undergoes nucleophilic aromatic 
addition with one of the amine groups as the nucleophile and the meta position of the 
methoxybenzene ring as the electrophile, effectively displacing copper (III). Cu3+ reduces to 
Cu1+ via reductive elimination. 
This Chan-Lam method to synthesize diphenylamine (1) proved to be extremely efficient, 
with an 82% yield after purification by flash chromatography. In addition to high yield, this 
mechanism allows for many iodination places. When this experiment was carried out with 2-
fluoro-4-iodoaniline, we obtained iodinated diphenylamine (1) in 66% yield. One could imagine 
that starting with an iodinated phenylboronic acid could yield many different placements of 
iodine in the synthesis of a photolabile T-06 analog. 
 
Figure 11. Possible iodinated diphenylamines (1). The asterisks indicate places of iodination. The blue 
asterisk indicates 2-fluoro-4-iodo-N-(3-methoxyphenyl)aniline, which has been synthesized in 66% yield. 
 
Figure 11 above shows all of the possible iodinated diphenylamines (1) that could be 
synthesized from the Chan-Lam mechanism, if the appropriate starting material could be 
obtained. Notice that iodination at the carbon para to methoxy must be avoided because of the 










2.2   Synthesis of 1-(2-fluorophenyl)-6-methoxyisatin (1-(2-fluorophenyl)-6-
methoxyindoline-2,3-dione) (2) 
The synthesis of 1-(2-fluorophenyl)-6-methoxyisatin (2) (referred to as isatin) was done 
using the procedure from Leslie Kim ’08. This is a two-part reaction involving a Friedel-Crafts 
acylation. The mechanism of this reaction is shown in figure 12.  
 
Figure 12. Friedel-Crafts mechanism in the synthesis of isatin (2).  
The nucleophilic nitrogen of diphenylamine attacks the acyl chloride carbon in oxalyl 
chloride, and successfully makes the C-N bond. The AlCl3 catalyst then coordinates with the 
chloride on the other acyl chloride, essentially making the attached carbon slightly positively 
charged. This electrophilic carbon can then react with the carbons of the two benzene rings, and 
there is selectivity for the methoxy benzene ring over the fluoro benzene ring due to the 
activating nature of the methoxy group to the ortho and para positions of the ring. The fluoro 
substituent neither activates nor deactivates, thus giving selectivity to the methoxy benzene ring 
for the ring closure. The para-position carbon of the methoxy ring then interacts with the 
electrophilic carbon to form isatin (2). 
 
2.3   Synthesis of 3-amino-1-(2-fluorophenyl)-6-methoxyindolin-2-one hydrochloride (3) 
There were many attempts to synthesize 3-amino-1-(2-fluorophenyl)-6-methoxyindolin-



















This is a crucial step that determines whether early iodination of the compounds before this step 
is useful. Figure 13 shows the various intermediates and attempted steps taken in the synthesis of 
amine-HCl (3). 
 
Figure 13. Steps taken to synthesize Amine-HCl (3) from Isatin (2). Red text indicates the previously 
investigated method of synthesizing Amine-HCl, which resulted in deiodination. Black and grey text represents the 
various attempted methods in order to avoid deiodination. Methods shown in grey indicate reactions that resulted in 
complete recovery of the starting material. 
Below is a discussion of the various methods as mentioned in figure 13. Due to the 
complete recovery of starting material, use of unprotected imine and t-butyl protected imine 
methods will not be discussed. However, the experimental section will include the specific 
reagents and molar ratios of each reaction. 
2.3.1   Reduction of (E)-1-(2-fluorophenyl)-3-(hydroxyimino)-6-methoxyindolin-2-one (2) to 
3-amino-1-(2-fluorophenyl)-6-methoxyindolin-2-one hydrochloride (3) using TiCl3 
 
Figure 14. Proposed synthesis of amine-HCl (3) via reduction of oxime using TiCl3 
Isatin (2)
Oxime
Catalytic Hydrogenation Amine-HCl (3), dehalogenated
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Figure 14 shows the proposed steps in this reduction method. The synthesis of (E)-1-(2-
fluorophenyl)-3-(hydroxyimino)-6-methoxyindolin-2-one (referred to as oxime) was achieved 
using a procedure provided by Leslie Kim.22 The oxime was conveniently synthesized by 
reacting isatin (2), hydroxylamine hydrochloride, and sodium carbonate in a solution of 95% 
ethanol. Direct reduction of oxime to amine was done following a mild procedure by Leeds and 
Kirst.24 This involved the reduction of the carbon nitrogen double bond using a mild sodium 
cyanoborohydride reagent and titanium (III) chloride as a catalyst in a methanol solvent system. 
The 1H-NMR spectrum of the crude product showed a change from the starting material 1H-
NMR, indicating that some kind of reduction did occur in this reaction. However, the crude 1H-
NMR resulted in two new different peaks at 5.3-5.4ppm, which lead us to believe that there were 











Figure 15. 1H-NMR of non-iodinated oxime (top) and reduced product (bottom). The four peaks labeled in pink 
are still apparent after the reduction, indicating that there is a high recovery of the starting material. The new peaks 
at 5.3-5.4ppm depict two different products. 
We suspect that the two different peaks we see at 5.3-5.4ppm arose from two rotational 
conformers. At the single bond between N and C of the fluorobenzene ring, there is a chance for 
rotation of the benzene ring. If they were true conformational isomers, the energy barrier to 
rotate freely would be relatively low and thus there should be unhindered rotation. In our case 
however, the two peaks in the 1H-NMR suggest that there is not free rotation. There is also a new 
A B C D
Two different 
kinds of C-H















chiral center at the five membered ring, which means that the proton at that chiral carbon is 
facing a certain direction. Thus, the fluoride of the fluorobenzene ring can either be facing 
towards or away from the proton, with both fluorobenzene rings being perpendicular to the rest 
of the molecule (figure 16). 
 
  
Figure 16. Two positions of the fluorobenzene ring as compared to the rest of the molecule. The fluoride 
substituent is perpendicular and either facing out or into the molecule. This rotation is distinguishable, as shown by 
the two peaks at 5.3-5.4ppm in the 1H-NMR in figure 15. 
 
The orientation of the fluoride in terms of the proton in the chiral carbon is important 
because it affects proton shifts, as fluoride is a highly electronegative substituent. In the case 
where the fluoride and the chiral proton are facing the same direction, we would expect the peak 
on the 1H-NMR to be shifted slightly downfield as compared to the case where the fluoride and 
the chiral proton are facing opposite directions. Additionally, the five membered ring is affected 
by the position of the fluoride, causing it to be torqued in such a way that results in a proton shift. 
Due to the low yield of product, high recovery of starting material, and difficulty in 














2.3.2   Protected imines: the use of (Z)-N-(1-(2-fluoro-4-iodophenyl)-6-methoxy-2-
oxoindolin-3-ylidene)-2-methylpropane-2-sulfinamide (2.1) as an intermediate 
 
Figure 17. Schematic diagram of sulfinimine as an intermediate.  
 
After the formation of isatin using a procedure implemented by Kim22, the use of (Z)-N-
(1-(2-fluoro-4-iodophenyl)-6-methoxy-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfinamide 
(2.1) (sulfinimine for short) as an intermediate in synthesizing amine-HCl was investigated. The 
overall process is as follows: synthesis of sulfinimine (2.1), reduction to N-(1-(2-fluoro-4-
iodophenyl)-6-methoxy-2-oxoindolin-3-yl)-2-methylpropane-2-sulfinamide (2.2) (referred to as 
sulfinamide), then conversion to amine-HCl (3) (figure 17). 
The reason we chose N-sulfinyl group as a particular auxiliary to imine was due to its 
highly activating feature of the C=N bond for addition reactions as well as its ease of cleavage 
under mild acid conditions. In the synthesis of sulfinimine (2.1) using a one-pot procedure from 
Davis et al.25, titanium (IV) ethoxide is used as a catalyst that acts as a Lewis acid to activate the 

























































electrons on the amine group of 2-methylpropane-2-sulfinamide attack and replace the ketone. In 
order to avoid possible unwanted oxidation of the product, the crude product was not purified, 
though 1H-NMR of the crude product was taken for verification purposes. There was a 
noticeable peak at 1.4ppm that was integrating for nine protons, which confirmed the addition of 
the t-butyl group. 
Reduction of sulfinimine (2.1) was done following the procedure from Colyer et al.26 
using sodium borohydride and a mixture of THF and water as the solvent. Again, purification of 
the product was not done to avoid possible oxidation. However, there was a noticeable difference 
in the 1H-NMR of crude sulfinamide (2.2) product as compared to the 1H-NMR of crude 
sulfinimine (2.1), which gave us the motivation to go on further in the synthesis.  
Using methanol and HCl, the sulfinyl group was cleaved off of the amine group to 
synthesize amine-HCl (3).27 The product was almost immediately taken to the next reaction, 
which was the EDC-coupling reaction to synthesize T-07 (4), the precursor to T-06.22 The 1H-
NMR of the aromatic region of T-07 (4) showed an integration of 14 protons (figure 18), while 




Figure 18. 1H-NMR of hydroxy T-07. The spectrum above is only showing the aromatic region of this 1H-NMR. 
Integration in regions from 6.5ppm-9.0ppm shows that there are 14 protons, while the expected integration is 13 
protons.  
 
The extra peak that was seen suggested the presence of a hydroxyl group in place of the 
fluoride. The relatively clean coupling pattern in this aromatic region also supported the idea of 
the cleavage of fluoride, since fluoride couples to protons and makes the 1H-NMR data look far 
more complicated. In order to verify the presence of a hydroxyl group, an 1H-NMR of T-07 with 














Figure 19. 1H-NMR of hydroxy T-07 with D2O. Integration in regions from 6.5ppm-9.0ppm shows that there are 
12 protons, indicating a loss of two hydrogen-bonding protons as compared to figure 18. One of the H-bonding 
proton is the N-H proton, and the other proton was deduced to be a proton from an -OH bond.  
The disappearance of the peaks at 8.9ppm and 7.7ppm is shown in the above figure. In 
order to be certain that replacement of fluoride is reproducible, this procedure was repeated again 
with the same result. Suspecting that the titanium catalyst might be the culprit, the synthesis of 
sulfinimine (2.1) was done with a different catalyst, pyridinium p-toluenesulfonate (PPTS), using 
a procedure provided by Liu et al.28 Unfortunately the procedure involving PPTS resulted in a 
complete recovery of the starting material and PPTS proved to be an ineffective catalyst.  
Because this hydroxy T-07 was a novel compound to the Haines lab, it was unclear 
whether this would be effective in biological testing. However, past research has highlighted the 
importance of fluorine in pharmaceuticals. This is evident in the abundance of fluorinated drugs, 
which make up roughly 20% of all pharmaceuticals as of 2007. In a lead compound, 










and excretion.29 Additionally, Meng et al.30 designed and synthesized fluorinated analogs of 
GLP-1 to test for their stability and efficacy. Overall reports showed that fluorinated GLP-1 
analogs had higher proteolytic stability as well as higher efficacy, or biological activity. 
Knowing these pieces of information about fluorinated compounds, it is very probable that the 
fluoride on T-06 also plays an important role in binding and activity. Of course, the exact role 
that fluoride plays in T-06 when binding to GLP-1R is unclear until biological testing is done.  
The furthest compound that was synthesized using this method of reductive amination 
was T-07. This was due to several reasons, the biggest of which was percent yield. With each 
successive reaction, the yield decreased significantly. Another reason is the high probability of 
the loss in biological activity due to the loss of fluoride.  
2.3.3   Formation of the C-N bond in amine-HCl (3) via SN2 mechanism 
This is a method that uses an SN2 mechanism to synthesize amine-HCl (3). Two of the 
most crucial components of an SN2 mechanism are the presence of a good leaving group and a 
good nucleophile. In order to make the ketone of isatin (2) a good leaving group, we chose to 
reduce it to a hydroxyl group, and then displace the hydroxyl with a chloride. Figure 20 shows 
the schematic diagram of the proposed synthesis via SN2.  
 


































The t-butylamine group was chosen to be the amine-protecting group because of its 
relative ease of cleavage. Leclerc et al.31 reported that a simple treatment with hydrochloric acid 
and methanol in reflux for short period of time would deprotect the amine. In addition, the t-
butyl group is slightly electron donating to the nitrogen, making it a decent nucleophile in this 
SN2 reaction. 
The first step in this method is a reduction of isatin to 1-(2-fluorophenyl)-3-hydroxy-6-
methoxyindolin-2-one (2.3) (referred to as hydroxyoxindole). Sodium borohydride was used as a 
reducing agent, and the procedure was modeled after Tamami and Mahdavi.32 When this reaction 
was carried out for the first time, the presence of the hydroxyoxindole (2.3) was confirmed with 
GC-MS and the product was purified with flash chromatography. Purification of 
hydroxyoxindole (2.3) was followed by displacement of hydroxy with chloride and SN2 reaction 
with t-butylamine. Purification of the crude product resulted in very little pure t-butylamine (2.4) 
and thus the subsequent deprotection to Amine-HCl (3) could not be done. 
In order to obtain more t-butylamine (2.4), the reduction reaction to hydroxyoxindole 
(2.3) was done for the second time. This time, the GC-MS of the crude product did not show the 
presence of hydroxyoxindole (2.3). The same reaction was repeated twice with comparable 
results. Since all of the reaction conditions were kept the same, we suspected a possible defect in 
the starting reagents. 1H-NMR was taken of isatin (2), which proved the compound to be intact. 
Since the only other reagent in this reaction was NaBH4, we decided to test for possible 
decomposition in a simpler reduction reaction with cyclohexanone (figure 21).   
 







GC-MS was taken of the crude product of the reduction reaction to cyclohexanol. The 
data showed no peaks that could account for cyclohexanol, leading us to believe that NaBH4 has 
fallen apart over the years that it has been opened. NaBH4 is air and moisture sensitive and the 
suggested storing condition for NaBH4 is in a tightly closed container in a dry place.33 Since the 
storage conditions were not strictly regulated especially during the humid summers, it was 




















In the investigation of a novel method of synthesizing amine-HCl (3), significant 
progress was made in the first step of the overall synthesis of T-0632. The Chan-Lam coupling 
reaction to synthesize diphenylamine (1) proved to be extremely convenient and efficient. Once 
diphenylamine (1) was converted to isatin (2), several attempts were made in the reduction of 
isatin (2) to amine-HCl (3). Such methods involved intermediates like oxime, imine, protected 
imine, and hydroxyoxindole. Some methods produced surprising results, such as the replacement 
of the fluoride with a hydroxyl in the case of using sulfinimine as an intermediate.  
As of now, further research needs to be done in the reductive amination step to preserve 
the iodine. Iodinating early on in the synthesis is practical once a reductive amination method is 
found, and such early iodination would lead to different analogs of azido-T-06 that will help in 
























Unless stated otherwise, all reagents were obtained from Sigma-Aldrich or Alfa Aesar and used 
without further purification. Thin-layer chromatography (TLC) was done on Merck 60-F254 pre-
coated silica gel plates, and visualized using exposure to UV light (254nm). Column 
chromatography was done using Sigma Aldrich silica gel (60 Å, 70-230 mesh) or Biotage flash 
silica cartridges for the SP1 system. 1H-NMR and 13C-NMR spectra were obtained using a 
Bruker 300 MHz WIN-NMR spectrometer and TMS was used as an internal standard. Unless 
otherwise noted, deuterated chloroform was the solvent used in NMR spectroscopy. Gas 
chromatography mass spectrometry was obtained using an Agilent 6890N Network GC System 
coupled with an electron impact Agilent 5937 Network Mass Selective Detector. Unless 
otherwise noted, the parameters used in GCMS is as follows: Tinitial = 120°C, Tfinal = 325°C, rate 
= 20°C/sec; split mode (inlet); mobile phase = He(g); constant flow mode, flow rate 1.0mL/min; 
injection volume 1.0µL, pressure 11.6 psi. 
4.1   Synthesis of 2-fluoro-N-(3-methoxyphenyl)aniline (1) 23 
 
All of the glassware and stir bar used in this reaction were 
stored in an oven (100°C) for more than 24 hours before 
the start of the experiment. In a 500mL round bottom 
flask, 3-methoxyphenylboronic acid (0.962g, 6.33mmol), Cu(OAc)2 (0.077g, 0.422mmol), and 
myristic acid (0.193g, 0.844mmol) were added. A rubber septum cap was attached and the 













and 2-fluoroaniline (0.408mL, 4.23mmol) were added by syringe in this order. The mixture was 
stirred at a high rate for 24 hours, diluted with ethyl acetate, and vacuum filtered through a silica 
gel plug to remove copper and salts. The mixture was purified by flash chromatography (1% to 
3% ethyl acetate in hexanes) to yield 82% of 2-fluoro-N-(3-methoxyphenyl)aniline. The identity 
of diphenylamine (1) was confirmed using 1H-NMR in CDCl3 and GC-MS.  
GC-MS: m/e = 217 (M+); 1H-NMR (CDCl3): δ7.0ppm (td, 1H, H6), δ7.2ppm (t, 1H, H5’), 
δ7.1ppm (dd, 1H, H3), δ7.0ppm (t, 1H, H5), δ6.82ppm (m, 1H, H4), δ6.66ppm (d, 1H, H4’), 
δ6.64ppm (d, 1H, H2’), δ6.52ppm (dd, 1H, H6’), δ5.8ppm (s, 1H, NH), δ3.75ppm (s, 3H, –
OCH3).  
4.2   Synthesis of 1-(2-fluorophenyl)-6-methoxyisatin (2) 
The following procedure is adapted from Kim’s thesis.22 Glassware and syringes were oven-
dried overnight for the preparation of this reaction. Oxalyl chloride (6.2mmol) and amylene 
stabilized chloroform (4.5ml) were added to a reaction flask over an ice and salt bath. In a 
separate flask, diphenylamine (2.9mmol) and amylene stabilized chloroform (4.5ml) were mixed 
and the solution was added dropwise to the reaction flask over a 5-10 minute period. After all of 
the mixture has been added, the reaction flask was kept on ice for 10 minutes and then taken off 
of the ice/salt bath. The mixture was then stirred at room temperature for two hours. At the end 
of two hours, the chloroform was evaporated using a rotovap. Chloroform (5ml) was added and 
evaporated twice to remove unreacted oxalyl chloride. To this dark green oily mixture, 10ml of 
dichloromethane was quickly added and cooled in an ice saltwater bath. Aluminum chloride 
(2.9mmol) was added to the reaction flask and the mixture was warmed to room temperature. 
The reaction was stirred for 48 hours at room temperature before being poured over 10 grams of 
ice in 2.1ml of 2M HCl. The isatin was extracted with dichloromethane, and washed twice with 
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10% NaHCO3. The organic layer was dried with anhydrous MgSO4, filtered through phase 
paper, and the solvent was evaporated. The crude product was purified by flash chromatography 
(15-25% EtAc in hexanes). GC-MS: m/e = 271 (M+); 1H-NMR (CDCl3): δ7.7ppm (d, 1H, H 
meta to –OCH3), δ7.2-7.6ppm (m, 4H of the fluorobenzene ring), δ6.62ppm (dd, 1H, H para to 
nitrogen), δ6.16ppm (d, 1H, H between –OCH3 and nitrogen), δ3.85ppm (s, 3, H of –OCH3).  
4.3   Reduction of (E)-1-(2-fluorophenyl)-3-(hydroxyimino)-6-methoxyindolin-2-one 
(oxime) using TiCl3 24 
Oxime (0.14g, 0.49mmol), NaCNBH4 (0.09g, 1.46mmol), ammonium acetate (0.415g) and 
methanol (9.5ml) were added to the reaction flask. TiCl3 (0.68ml, 2.2 eq) was measured in a 
graduated cylinder and added dropwise to the reaction flask over a 10-minute period. After the 
addition of TiCl3, the flask was sealed with a septum cap and flushed with (+) N2 gas for 10 
minutes. The mixture was stirred overnight at room temperature. The mixture was diluted with 
water and extracted with dichloromethane. The aqueous layer was taken and base was added 
until the pH was raised to around 9.5, which was checked using a pH strip. The product was 
extracted with dichloromethane, dried with anhydrous MgSO4, filtered through phase paper, and 
the solvent was evaporated. 1H-NMR showed two different conformers, as explained in the 
results section. 1H-NMR (CDCl3): δ9.2ppm (s, 1H, -OH of oxime), δ8.07ppm (d, 1H, H meta to 
–OCH3), δ 7.0-7.6ppm (m, 4H of the fluorobenzene ring), δ6.6ppm (dd, 1H, H para to nitrogen), 
δ6.15ppm (d, 1H, H between –OCH3 and nitrogen), δ5.3-5.4ppm (s, two different H, chiral H), 




4.4   Synthesis of 1-(2-fluorophenyl)-3-imino-6-methoxyindolin-2-one (unprotected imine) 
This procedure was following the synthesis provided by Kumar et al.34 Isatin (0.1g, 0.369mmol) 
was dissolved in 10ml of glacial acetic acid in a beaker. In a separate beaker, ammonium 
chloride (0.02g, 0.369mmol) was dissolved in 10ml of glacial acetic acid. These two solutions 
were combined into a roundbottom flask, and refluxed for 3-4 hours using a heating mantle and a 
variac set to 40V. After the reaction the solution was cooled to room temperature, diluted with 
water, and the product was extracted several times with dichloromethane. The organic layer was 
washed several times with water in order to wash out the remaining acetic acid and ammonium 
chloride. The organic layer was dried with anhydrous MgSO4, filtered through phase paper, and 
evaporated. 1H-NMR was taken of the crude product, which confirmed a complete recovery of 
the starting material. This procedure was also done with ammonium acetate instead of 
ammonium chloride with the same result. Additionally, the molar equivalence of 
isatin:ammonium acetate was increased from 1:1 to 1:5 with the same result.  
4.5   Synthesis of t-butylimine 
Procedure from Matesic et al.35 was referenced in this reaction. Molecular sieves (3Å, 1g) were 
added to a roundbottom flask. The flask was stored in an oven overnight at 120°C. The flask was 
taken out of the oven and cooled to room temperature. Iodoisatin (0.1g, 0.25mmol) and EtOAc 
(7.5ml) was added to the reaction flask and stirred for 10 minutes. T-butylamine (0.018g, 
0.25mmol) was added and the mixture was further stirred for five minutes before the addition of 
glacial acetic acid (0.2ml per 0.1g of isatin). The mixture was refluxed for 1.5 hours, the sieves 
were filtered through phase paper, and the solution was evaporated. 1H-NMR of the crude 
product showed the recovery of the starting material.  
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4.6   Synthesis of Sulfinimine (2.1)25 
 
The reaction flask was flushed with nitrogen gas for 20 minutes before any reagent was added. 
Isatin (0.256g, 0.645mmol), 2-methylpropane-2-sulfinamide (0.0782g, 0.645 mmol), and 
titanium(IV) ethoxide (0.676ml, 3.23 mmol) were added to the flask and refluxed in 10 ml of 
dichloromethane for five hours. The progress of the reaction was monitored by TLC. Ice water 
(10ml) was added to the mixture, vacuum filtered through celite, and the solids were washed 
with dichloromethane. The organic layer was taken after separation using a separatory funnel, 
dried with anhydrous MgSO4, and the solvent was evaporated. 1H-NMR was run. In order to 
prevent unwanted oxidation the crude sulfinimine mixture was not purified. 
 
 
4.7   Synthesis of Sulfinamide (2.2)26 
In a round bottom flask, sulfinimine (0.30g, 0.6 mmol) and 30ml of THF:water (98:2) were 
added and placed in a bath of THF and dry ice. Sodium borohydride (0.068g, 1.8 mmol) was 
added to the flask and stirred for three hours. The dry ice was added to the bath intermittently for 
two hours. The reaction flask was brought to room temperature for the remaining hour. The 
mixture was evaporated and 20ml of dichloromethane was added. No extraction was done using 
a separatory funnel. The solution was dried with anhydrous MgSO4, filtered through phase paper, 
and the solvent was evaporated.  
 
4.8   Synthesis of Amine-HCl (3) from Sulfinamide (2.2)27 
In a reaction flask, sulfinamide (0.30g, 0.6 mmol) and 20 ml of 0.4M anhydrous HCl (4M HCl 
diluted in methanol) was combined and stirred at room temperature for five hours. After the 
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reaction, the solvent in the mixture was evaporated. 1H-NMR was taken of the crude product but 
no peaks were discernable.  
 
4.9   Synthesis of T-07 (4) (procedure taken from Kim22) 
From the previous amine-HCl reaction, the yield was assumed to be 60% for the purposes of 
molar ratios. In the roundbottom containing amine-HCl (0.156g, 0.36mmol), isoquinoline-3-
carboxylic acid (0.076g, 0.396 mmol) and dichloromethane (5ml). The mixture was cooled in an 
ice bath. The following reagents were added to the roundbottom flask in this order: 
diisopropylethylamine (0.063ml, 0.36mmol), hydroxybenzotriazole (0.054g, 0.396mmol), and 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.076g, 0.396mmol). The 
mixture was then warmed to room temperature and stirred overnight. The mixture was quenched 
with water and the product was extracted with dichloromethane. The product was dried with 
anhydrous MgSO4 and the solvent was evaporated. The crude product was purified by flash 
chromatography (20-60% EtOAc/Hex). 1H-NMR (CDCl3): δ8.95ppm (s, 1H, -NH), δ8.9ppm (d, 
1H, isoquinoline ortho to C=O), δ8.5ppm (s, 1H, isoquinoline meta to C=O), δ7.9-7.95ppm (2d, 
2H, H para and meta to –OH), δ6.85-7.75ppm (m, 5H, isoquinoline and H ortho to –OH), 
δ7.7ppm (s, 1H, -OH), δ7.15ppm (d, 1H, H meta to –OCH3), δ6.75ppm (d, 1H, H ortho to N), 
δ6.6ppm (dd, 1H, H para to N), δ5.5ppm (m, 1H, chiral H), δ3.65ppm (s, 3H, –OCH3).  
 
4.10   Synthesis of hydroxyoxindole (2.3) 
This procedure was following the procedure provided by Tamami and Mahdavi.32 Isatin (0.27g, 
1mmol), sodium borohydride (0.019g, 0.5mmol), and 15-20ml of wet dioxane were placed in a 
roundbottom flask and stirred at room temperature for 24 hours. During this time, the 
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roundbottom flask was covered with a septum cap and an escape needle was placed. A slight 
color change in the mixture was observed from orange to a lighter shade of orange. When the 
reaction ended, the mixture was vacuum filtered through a short column of silica and washed 
thoroughly with dichloromethane. The solution was then dried with anhydrous MgSO4, filtered 
through fluted filter paper, and the solvent was evaporated. The crude product was purified by 
flash chromatography (50-100% DCM/Hex followed by 2-3% MeOH/DCM). GC/MS: m/e = 
273 (M+). 
4.11   Chlorination of hydroxyoxindole32 and subsequent amination via SN236 
Hydroxyoxindole (0.16g, 0.59mmol), pyridine (0.05ml, 0.64mmol), and non-anhydrous 
chloroform (3ml) were combined in a flask. In a separate reaction flask, thionyl chloride 
(0.046ml, 0.64mmol) and chloroform (1ml) were combined over an ice bath. While the mixture 
over ice was stirring, the hydroxyoxindole solution was added to the reaction flask dropwise over 
a five-minute period. After all of the solution was added to the reaction flask, it was taken off the 
ice bath and heated to 60°C using a variac set to 25V. The mixture was stirred for three hours, 
and the color of the solution changed from yellow to a darker shade of yellow. The mixture was 
cooled to room temperature and then t-butylamine (1.76mmol) was added to the reaction flask 
and stirred at room temperature for 24 hours. The mixture turned into a reddish, brownish liquid. 
The solution was poured into a separatory funnel and NaHCO3 was added. The organic layer was 
collected with several washes using dichloromethane, dried with anhydrous MgSO4, filtered 
through phase paper, and the solvent was evaporated. The crude product was purified by flash 
chromatography (50-100% EtOAc/Hex followed by 10% MeOH/DCM). The isolated product 
had absorbances on 1H-NMR (CDCl3) that indicated successful addition of the t-butyl group, 
though replication of the procedure and further analysis is needed.  
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